Immune Checkpoint Inhibitors Clinical Trails Analysis

Table Of Contents

Excel Deliverable
1.Summary Dashboard
1.1. Pipeline Review
1.2. Clinical Trials Analysis
1.3. Analysis of Clinical Trial Results-related Publications
1.4. Analysis of Clinical Trial Results-related Publications, 2020-2021
1.5. Estimated Time to Launch Analysis

2. Contemporary Product Pipeline Dataset

3. Clinical Trials Dataset

4. Clinical Trial Results-related Publications Dataset

5. Clinical Trial Results Analysis Dataset

6. Estimated Time to Launch Dataset

7. Appendices

PowerPoint Deliverable
1. Context

2. Project Approach

3. Project Objectives

Section I

4. Executive Summary

Section II
5. Analysis of Clinical Trial Results
5.1. Overview
5.2. Scope and Methodology
5.3. PD-1 & PD-L1 Inhibitors: Phase I Trials
5.4. PD-1 & PD-L1 Inhibitors: Phase II Trials
5.5. PD-1 & PD-L1 Inhibitors: Phase III Trials
5.6. Concluding Remarks

Section III
6. Contemporary Product Pipeline Dataset
6.1. Overview
6.2. PD-1 & PD-L1 Inhibitors Pipeline
6.2.1. Analysis by Biological Target
6.2.2. Analysis by Type of Molecule
6.2.3. Analysis by Phase of Development
6.2.4. Analysis by Mechanism of Action
6.3. PD-1 & PD-L1 Inhibitors: Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.4. Concluding Remarks

Section IV
7. Clinical Trials Analysis
7.1. Overview
7.2. PD-1 & PD-L1 Inhibitors: Clinical Trials
7.2.1. Analysis by Trial Registration Year
7.2.2. Analysis by Trial Phase
7.2.3. Analysis by Enrolled Patient Population
7.3.4. Analysis by Study Design
7.3.5. Analysis by Sponsor / Collaborator
7.3.6. Most Active Industry Players: Analysis by Number of Registered Trials
7.3.7. Most Active Non-Industry Players: Analysis by Number of Registered Trials
7.3.8. Analysis by Target Therapeutic Area
7.3.9. Geographical Analysis by Number of Registered Trials
7.3.10. Geographical Analysis by Enrolled Patient Population

Section V
8. Clinical Trial Results-related Publications Dataset
8.1. Overview
8.2. Scope and Methodology
8.3. PD-1 & PD-L1 Inhibitors: List of Clinical Trial-related Publications
8.3.1. Analysis by Year of Publication
8.3.2. Analysis by Biological Target
8.3.3. Analysis by Target Therapeutic Area
8.3.4. Key Journals: Analysis by Number of Publications
8.3.5. Key Journals: Analysis by Impact Factor
8.3.6. Most Popular First Authors: Analysis by Number of Publications
8.4. Concluding Remarks

Section VI
9. Estimated Time to Launch
9.1. Overview
9.2. Scope and Methodology
9.3. PD-1 & PD-L1 Inhibitors: Estimated Time to Launch for Novel Drug Candidates
9.4. Concluding Remarks

Section VII
10. Conclusion

Section VIII
11. Appendices I: Tabulated Data

12. Appendices II: List of Companies & Organizations

List of Companies

Please reach out to our team for the details.

Source: acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21660